Medtronic: Use of the temporary glycemic target feature in the medtronic MiniMed 780G advanced hybrid closed loop system: a real-world evidence study

Abstract Aim The MiniMed 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work). Methods Real-world data from 1002 randomly selected users of the MiniMed 780G and MiniMed 670G systems were used to investigate the TT functionality (n = 501 MiniMed 780G users, n = 501 MiniMed 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0-4, 4-8, 8-12, 12-16, 16-20 and 20-24 h after TT initiation). Results CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods. Conclusions These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety. Access this article Subscribe and save Buy Now Price excludes VAT (USA) Tax calculation will be finalised during checkout. Instant access to the full article PDF. References Grosman B, Roy A, Lintereur L, Turksoy K, Benedetti A, Cordero TL, Vigersky RA, McVean J, Rhinehart AS, Cohen O (2024) A peek under the hood: explaining the MiniMed 780G algorithm with meal detection technology. Diabetes Technol Ther 26(S3):17-23. Castañeda J, Mathieu C, Aanstoot HJ, Arrieta A, Da Silva J, Shin J, Cohen O (2022) Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metab 24(11):2212-2221. O'Neal DN, Zaharieva DP, Morrison D, McCarthy O, Nørgaard K (2024) Exercising safely with the MiniMed 780G automated insulin delivery system. Diabetes Technol Ther 26(S3):84-96. Moser O, Zaharieva DP, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, Danne T, Davis EA, Dovč K, Forlenza GP, Gillard P, Hofer SE, Hovorka R, Jacobs PG, Mader JK, Mathieu C, Nørgaard K, Oliver NS, O'Neal DN, Pemberton J, Rabasa-Lhoret R, Sherr JL, Sourij H, Tauschmann M, Yardley JE, Riddell MC (2025) The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia 68(2):255-280. Dovc K, Battelino T, Beck RW, Sibayan J, Bailey RJ, Calhoun P, Turcotte C, Weinzimer S, Smigoc Schweiger D, Nimri R, Bergenstal RM (2022) Impact of temporary glycemic target use in the hybrid and advanced hybrid closed-loop systems. Diabetes Technol Ther 24(11):848-852. CareLink software. . Accessed 25 July 2024 Castañeda J, Arrieta A, van den Heuvel T, Battelino T, Cohen O (2024) Time in tight glucose range in type 1 diabetes: predictive factors and achievable targets in real-world users of the MiniMed 780G system. Diabetes Care 47(5):790-797. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 42(8):1593-1603. American Diabetes Association Professional Practice Committee (2025) 6 Glycemic goals and hypoglycemia: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S128-S145. Grassi B, Gómez AM, Calliari LE, Franco D, Raggio M, Riera F, Castro M, McVean J, van den Heuvel T, Arrieta A, Castañeda J, Cohen O (2023) Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system. Diabetes Obes Metab 25(6):1688-1697. Zaharieva DP, Morrison D, Paldus B, Lal RA, Buckingham BA, O'Neal DN (2023) Practical aspects and exercise safety benefits of automated insulin delivery systems in type 1 diabetes. Diabetes Spectr 36(2):127-136. Maran A, Pavan P, Bonsembiante B, Brugin E, Ermolao A, Avogaro A, Zaccaria M (2010) Continuous glucose monitoring reveals delayed nocturnal hypoglycemia after intermittent high-intensity exercise in nontrained patients with type 1 diabetes. Diabetes Technol Ther 12(10):763-768. Riddell MC, Milliken J (2011) Preventing exercise-induced hypoglycemia in type 1 diabetes using real-time continuous glucose monitoring and a new carbohydrate intake algorithm: an observational field study. Diabetes Technol Ther 13(8):819-825. Basu R, Johnson ML, Kudva YC, Basu A (2014) Exercise, hypoglycemia, and type 1 diabetes. Diabetes Technol Ther 16(6):331-337. Funding OC, TH, JC and JBS are employed by Medtronic. Author information Authors and Affiliations Medtronic International Trading Sàrl, Tolochenaz, Switzerland Jeremy Basset-Sagarminaga, Tim van den Heuvel, Javier Castañeda & Ohad Cohen Contributions All authors were involved in the analysis of data, writing of the manuscript and review of the manuscript. Corresponding author Correspondence to . Ethics declarations Conflict of interest Jeremy Basset-Sagarminaga is a current employee of Medtronic, the manufacturer of the MiniMed 780G advanced hybrid closed loop system. Tim van den Heuvel is a current employee of Medtronic, the manufacturer of the MiniMed 780G advanced hybrid closed loop system. Javier Castañeda is a current employee of Medtronic, the manufacturer of the MiniMed 780G advanced hybrid closed loop system. Ohad Cohen is a current employee of Medtronic, the manufacturer of the MiniMed 780G advanced hybrid closed loop system. Ethical approval Editorial support was provided by Jayne Smith-Palmer at Covalence Research Ltd; editorial support was funded by Medtronic. Additional information Communicated by Agostino Consoli, M.D. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Part of this work has been previously presented as an oral presentation at 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), 6-9th March 2024, Florence, Italy. Rights and permissions Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.